Re-evaluation of a Fibrillin-1 Gene Variant of Uncertain Significance Using the ClinGen Guidelines|RISS 상세보기

다국어 초록 (Multilingual Abstract)

Background: Marfan syndrome (MFS) is caused by fibrillin-1 gene (FBN1) variants. Mutational hotspots and/or well-established critical functional domains of FBN1 include cysteine residues, calcium-binding consensus sequences, and amino acids related to interdomain packaging. Previous guidelines for variant interpretation do not reflect the features of genes or related diseases. Using the Clinical Genome Resource (ClinGen) FBN1 variant curation expert panel (VCEP), we re-evaluated FBN1 germline variants reported as variants of uncertain significance (VUSs).
Methods: We re-evaluated 26 VUSs in FBN1 reported in 161 patients with MFS. We checked the variants in the Human Genome Mutation Database, ClinVar, and VarSome databases and assessed their allele frequencies using the gnomAD database. Patients’ clinical information was reviewed.
Results: Four missense variants affecting cysteines (c.460T>C, c.1006T>C, c.5330G>C, and c.8020T>C) were reclassified as likely pathogenic and were assigned PM1_strong or PM1. Two intronic variants were reclassified as benign by granting BA1 (stand-alone). Four missense variants were reclassified as likely benign. BP5 criteria were applied in cases with an alternate molecular basis for disease, one of which (c.7231G>A) was discovered alongside a pathogenic de novo COL3A1 variant (c.1988G>T, p.Gly633Val).
Conclusions: Considering the high penetrance of FBN1 variants and clinical variability of MFS, the detection of pathogenic variants is important. The ClinGen FBN1 VCEP encompasses mutational hotspots and/or well-established critical functional domains and adjusts the criteria specifically for MFS; therefore, it is beneficial not only for identifying pathogenic FBN1 variants but also for distinguishing these variants from those that cause other connective tissue disorders with overlapping clinical features.

번역하기

참고문헌 (Reference)

1 Najafi A, "Variant filtering, digenic variants, and other challenges in clinical sequencing: a lesson from fibrillinopathies" 97 : 235-245, 2020

2 Baudhuin LM, "Variability in gene-based knowledge impacts variant classification : an analysis of FBN1 missense variants in ClinVar" 27 : 1550-1560, 2019

3 Park Seon Young ; Lee Jong-Mi ; Kim Myung-Jin ; Chung Nack-Gyun ; Lee Jung Bok ; 김용환 ; 김명신, "Validation of Pathogenicity of Gene Variants in Fanconi Anemia Using Patient-derived Dermal Fibroblasts" 43 : 127-131, 2023

4 Comeglio P, "The importance of mutation detection in Marfan syndrome and Marfan-related disorders : report of 193 FBN1 mutations" 28 : 928-, 2007

5 Pepin MG, "The challenge of comprehensive and consistent sequence variant interpretation between clinical laboratories" 18 : 20-24, 2016

6 Malfait F, "The 2017 international classification of the Ehlers–Danlos syndromes" 175 : 8-26, 2017

7 Pepin MG, "Survival is affected by mutation type and molecular mechanism in vascular Ehlers–Danlos syndrome(EDS type IV)" 16 : 881-888, 2014

8 Schrenk S, "Structural and functional failure of fibrillin‑1 in human diseases(Review)" 41 : 1213-1223, 2018

9 Pisano C, "Risk of aortic dissection in patients with ascending aorta aneurysm: a new biological, morphological, and biomechanical network behind the aortic diameter" 4 : 33-, 2020

10 Overwater E, "Results of next-generation sequencing gene panel diagnostics including copy-number variation analysis in 810 patients suspected of heritable thoracic aortic disorders" 39 : 1173-1192, 2018